Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Exclusion Criteria

• •Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection
• •Abnormal liver function
• •Uncontrolled hypertension (systolic blood pressure \>=160 mmHg or diastolic blood pressure \>=95 mmHg)
• •Active or symptomatic viral hepatitis or chronic liver disease
• •History of pituitary or adrenal dysfunction
• •Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease or left ventricular ejection fraction of \<50% at baseline
• •Known brain metastasis
• •History of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study drug
• •Any acute toxicities due to prior chemotherapy or radiotherapy that have not resolved to a NCI-CTCAE (Version 4.0) Grade of \<=1
• •Prior systemic treatment with an azole drug (eg, fluconazole, itraconazole, ketoconazole) within 4 weeks of Cycle 1, Day 1
• •Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study
• •Participation in an investigational drug trial within 30 days prior to selection
• •Known hypersensitivity to abiraterone acetate, or to any of the components in the formulation